AbbVie News Center - News
Abb Vie Mediaroom. ...
Read Abbvie.mediaroom.com news digest here: view the latest Abb Vie Mediaroom articles and content updates right away or get to their most visited pages. Abbvie.mediaroom.com is not yet rated by Alexa and its traffic estimate is unavailable. It seems that Abb Vie Mediaroom content is notably popular in USA. We haven’t detected security issues or inappropriate content on Abbvie.mediaroom.com and thus you can safely use it. Abbvie.mediaroom.com is hosted with CloudFlare, Inc. (United States).
Content verdict: Safe
Website availability: Live
Last check:
-
N/A
Visitors daily -
N/A
Pageviews daily -
5
Google PR -
N/A
Alexa rank
Best pages on Abbvie.mediaroom.com
-
AbbVie (NYSE: ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for...
-
AbbVie (NYSE: ABBV) today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company,...
-
News January 28, 2026 January 16, 2026 Press Kits Our press kits are designed to provide journalists with a broad range of background information on our company. January 28, 2026 January 1...
Abbvie.mediaroom.com news digest
-
2 years
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strength...
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage...
-
2 years
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artifi...
Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation...
-
2 years
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mir...
Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant...
-
2 years
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluati...
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in...
Domain history
| Web host: | CloudFlare, Inc. |
| Registrar: | CSC Corporate Domains, Inc. |
| Registrant: | Not Disclosed Not Disclosed (Not Disclosed) |
| Updated: | January 29, 2025 |
| Expires: | February 02, 2026 |
| Created: | May 05, 2001 |
Whois record
Safety scores
Trustworthiness
GoodChild safety
N/A
